Related Experiment Video

Updated: Apr 20, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K

Immunization for Streptococcus pneumoniae infections in high-risk children

    Pediatrics
    |November 26, 2014
    PubMed

    Insights

    Pneumococcal conjugate vaccine (PCV13) is now recommended for children aged 6-18 with specific health conditions. This aims to further reduce invasive pneumococcal disease (IPD) in at-risk pediatric populations.

    Area of Science:

    • Pediatric Infectious Diseases
    • Vaccinology
    • Public Health

    Background:

    • Routine pneumococcal conjugate vaccines (PCV7, PCV13) significantly reduced invasive pneumococcal disease (IPD) since 2000.
    • Certain pediatric populations remain at elevated risk for IPD.

    Purpose of the Study:

    • To provide updated recommendations for PCV13 use in children aged 6-18 years.
    • To identify specific at-risk pediatric groups benefiting from PCV13 vaccination.

    Main Methods:

    • Review of current epidemiological data on IPD incidence.
    • Analysis of clinical guidelines from the Advisory Committee on Immunization Practices and the American Academy of Pediatrics.

    Main Results:

    • PCV13 is recommended for children aged 6-18 with specific risk factors for IPD.
    • A single dose of PCV13 is advised for these at-risk children.

    Conclusions:

    • Expanded PCV13 use enhances protection against IPD in high-risk children.
    • Recommendations for healthy children and PPSV23 use remain unchanged.

    Keywords:
    PCV13PPSV23immunizationinvasive pneumococcal diseasepneumococcal vaccine

    More Related Videos

    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

    Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

    Published on: April 5, 2019

    13.5K
    Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

    Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

    Published on: September 11, 2020

    2.3K

    Related Concept Videos

    Pneumonia V: Nursing management and Prevention01:30

    Pneumonia V: Nursing management and Prevention

    Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
    The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
    Enhance airway patency
    Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
    4.1K
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
    16
    Pneumonia I: Introduction01:30

    Pneumonia I: Introduction

    Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
    Risk Factors
    Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
    1.4K
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    1.3K
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    393
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    1.1K